Literature DB >> 16411067

PRL secreting adenomas in male patients.

Antonio Ciccarelli1, Ermelinda Guerra, Michele De Rosa, Francesco Milone, Stefano Zarrilli, Gaetano Lombardi, Annamaria Colao.   

Abstract

Prolactinomas are the most frequent pituitary tumors and their frequency varies with age and sex, occurring most frequently in females between 20-50 yr-old. In men, hyperprolactinaemia is often present for many years without symptoms, as generally the most important symptoms are the decrease in libido and/or sexual potency both underestimated by the majority of the patients. Prolactin (PRL) plays a role in the process of spermatogenesis, and normal serum PRL levels are required for normal testicular function. On the other hand, hyperprolactinaemia has multiple negative effects on the gonadal axis. As a consequences hyperprolactinemic males show alteration of sexual potency and seminal fluid quality. Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16411067     DOI: 10.1007/s11102-005-5084-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  17 in total

Review 1.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

2.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

3.  Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro.

Authors:  M S Manandhar; J A Thomas
Journal:  Invest Urol       Date:  1976-07

4.  Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.

Authors:  M De Rosa; A Colao; A Di Sarno; D Ferone; M L Landi; S Zarrilli; L Paesano; B Merola; G Lombardi
Journal:  Eur J Endocrinol       Date:  1998-03       Impact factor: 6.664

5.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.

Authors:  Annamaria Colao; Antonella Di Sarno; Paolo Cappabianca; Francesco Briganti; Rosario Pivonello; Carolina Di Somma; Antongiulio Faggiano; Bernadette Biondi; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2003-03       Impact factor: 6.664

6.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

Authors:  Annamaria Colao; Giovanni Vitale; Paolo Cappabianca; Francesco Briganti; Antonio Ciccarelli; Michele De Rosa; Stefano Zarrilli; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.

Authors:  Michele De Rosa; Stefano Zarrilli; Giovanni Vitale; Carolina Di Somma; Francesco Orio; Libuse Tauchmanova'; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men.

Authors:  S J Winters
Journal:  J Androl       Date:  1991 May-Jun

Review 9.  Effect of prolactin on the prostate.

Authors:  L C Costello; R B Franklin
Journal:  Prostate       Date:  1994       Impact factor: 4.104

10.  Prolactin receptor expression in rat spermatogenic cells.

Authors:  E Hondo; M Kurohmaru; S Sakai; K Ogawa; Y Hayashi
Journal:  Biol Reprod       Date:  1995-06       Impact factor: 4.285

View more
  19 in total

Review 1.  [Influence of neurological diseases on partnership and sexuality. Particularly in view of multiple sclerosis and Parkinson's disease].

Authors:  D Goecker; D Rösing; K M Beier
Journal:  Urologe A       Date:  2006-08       Impact factor: 0.639

2.  A combined opiate agonist and antagonist treatment reduces prolactin secreting pituitary tumor growth.

Authors:  George Maglakelidze; Olivia Wynne; Dipak K Sarkar
Journal:  J Cell Commun Signal       Date:  2017-01-31       Impact factor: 5.782

3.  Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.

Authors:  Ilan Shimon; Dania Hirsch; Gloria Tsvetov; Eyal Robenshtok; Amit Akirov; Merav Fraenkel; Yoav Eizenberg; Dana Herzberg; Liat Barzilay-Yoseph; Anat Livner; Ilana Friedrich; Yossi Manisterski; Avraham Ishay; Uri Yoel; Hiba Masri
Journal:  Endocrine       Date:  2019-06-01       Impact factor: 3.633

Review 4.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

Review 5.  The role of testosterone in erectile dysfunction.

Authors:  Giovanni Corona; Mario Maggi
Journal:  Nat Rev Urol       Date:  2009-12-08       Impact factor: 14.432

6.  Women with prolactinomas presented at the postmenopausal period.

Authors:  Ilan Shimon; Marcello D Bronstein; Jonathan Shapiro; Gloria Tsvetov; Carlos Benbassat; Ariel Barkan
Journal:  Endocrine       Date:  2014-04-08       Impact factor: 3.633

Review 7.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 8.  The hormonal control of ejaculation.

Authors:  Giovanni Corona; Emmanuele A Jannini; Linda Vignozzi; Giulia Rastrelli; Mario Maggi
Journal:  Nat Rev Urol       Date:  2012-08-07       Impact factor: 14.432

9.  Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention.

Authors:  Frederick Yoo; Carmen Chan; Edward C Kuan; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2017-12-26

Review 10.  Improving Quality of Life in Patients with Pituitary Tumours.

Authors:  Iris Crespo; Alicia Santos; Eugenia Resmini; Elena Valassi; Maria Antonia Martínez-Momblán; Susan M Webb
Journal:  Eur Endocrinol       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.